Print

HVTN 100

NCT02404311

Trial Details:

I/II Ongoing
Pox-Protein Public-Private Partnership (P5) NIAID, HVTN, Bill and Melinda Gates Foundation, Medical Research Council, Sanofi Pasteur, Novartis Vaccines
ALVAC-HIV-C (vCP2438), Bivalent Subtype C gp120/MF59
?Healthy adults
RandD/trials/Lists/ClinicalTrialsList
1/1/2017
Canarypox Env gp120 C, gp41 B, gag B, protease B; Protein Env C
ALVAC-HIV (vCP2438) 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) IM injection as a single dose. Bivalent Subtype C gp120/MF59® -- 2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with